Gilead’s HIV franchise generated $19.612B in 2024, but faces future funding challenges. Learn why GILD stock is a "Hold" amid ...

"We tried not to make the same show — it's got younger voices, it's got a completely different feel and a completely different vibe," creator Bruce Miller says of the new Gilead-set project.

In the latest market close, Gilead Sciences (GILD) reached $112.39, with a +0.45% movement compared to the previous day. The stock outperformed the S&P 500, which registered a daily loss of 4.84%. On ...

PEPFAR had been set to lead the rollout of Gilead Science's lenacapavir, which has been hailed as a "miracle" of HIV ...

The final season of "The Handmaid's Tale," premiering April 8 on Hulu, expands the themes and story of Margaret Atwood's ...

This final season may be more of a cliffhanger than a conclusion. (A sequel is in the works.) The question it asks is: how ...

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some ...

As the sixth and final season lands on Hulu, THR’s chief TV critic reflects on how the dystopian series was shaped by the ...

Hulu announced that it is developing a series based on Margaret Atwood's 2019 novel "The Testaments," which is a follow-up to ...

Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...

With the FDA appearing to be undergoing major disruption under new leadership, BofA analyst Tim Anderson says one way to assess the risk from ...

Three other Bay Area companies — Mirum Therapeutics Inc. (Nasdaq: MIRM), Soleno Therapeutics Inc. (Nasdaq: SLNO) and Exelixis ...